Shanghai Industrial Holdings Limited (00363.HK) is an investment holding company primarily engaged in infrastructure facilities, environmental protection, real estate, and consumer products businesses in Hong Kong, the People's Republic of China, rest of Asia, and internationally. The company operates through four main segments: Infrastructure and environmental protection, encompassing investments in toll roads and bridges such as the three toll roads in Shanghai (Beijing-Shanghai Expressway Shanghai section, Shanghai-Kunming Expressway Shanghai section, Shanghai-Chongqing Expressway Shanghai section) and a 23.0584% stake in Hangzhou Bay Bridge, as well as water services, clean energy, sewage treatment, and solid waste treatment; Real Estate, including property development, investment, and hotel operations through subsidiaries like SI Urban Development (0563.HK) and SI Development (600748.SS) with projects in 11 major Chinese cities including Shanghai and Beijing; Consumer Products, featuring premium tobacco products from Nanyang Tobacco and printing services from Wing Fat Printing; and Comprehensive Healthcare, covering health care products and related initiatives. Founded in January 1996 and headquartered at Harcourt House in Wan Chai, Hong Kong, the company maintains a diversified geographic footprint with primary revenue from the PRC, supplemented by operations in Asia excluding Hong Kong and the PRC. Recent developments include a strategic investment in a closed-end fund for Hangzhou Bay Bridge in 2024 to enhance investment flexibility and liquidity; a proposed sale by an indirect subsidiary of its 23.0584% equity in Ningbo Hangzhou Bay Bridge Development in November 2024 for no less than RMB1.747 billion; subscription of HK$1.637 billion exchangeable bonds in Yuefeng Environmental in October 2023 to strengthen leadership in solid waste treatment; and a new RMB900 million pharmaceutical packaging procurement framework agreement with Shanghai Pharmaceuticals in October 2024, alongside ongoing big health expansions such as prior stakes in Shanghai Pharmaceutical Group.